While HIV treatment has come a long way over the decades, it still faces challenges. Specifically, HIV therapy such as integrase inhibitors have been associated with increased weight gain but the mechanism and extent of which has remained largely unknown. Listen in as Dave Hachey, HIV expert, and Geoff Wall discuss this and how it impacts medication selection when caring for patients with HIV.

The Gamechanger: 

• The risk of weight gain with integrase inhibitor and other potential HIV regimens should be discussed with patients
• Patients’ comorbidities should risk factors should be considered when determining an appropriate treatment regimen
• Studies suggest that the mechanism of weight gain from integrase inhibitors and older agents such as tenofovir alafenamide is different, although more research is needed

Show Segments: 

00:00 – Introductions

04:36 – HIV Treatment & Weight Gain 

07:27 – Integrase Inhibitors vs Tenofovir Alafenamide 

17:12 – The GameChanger

26:22 – Closing Remarks

Guest Bios:

David Hachey, PharmD, AAHIVP Professor Idaho State University

After graduating from the University of Rhode Island, Dr. Hachey completed a residency and fellowship in Family Medicine at Idaho State University. After, he stayed in Idaho and expanded his role with the College of Pharmacy and the Department of Family Medicine. Dr. Hachey has experience within the community setting and has also served as the director of the regional Ryan White HIV Clinic for the last 15-20 years. His vast experience gives him a unique perspective on the challenges pharmacists and patients face in preventing and managing HIV.   

Links to Resources: 

Excess Weight Gain with Integrase Inhibitors and Tenofovir Alafenamide Study

How to Claim CE:

CE is available for CEimpact members. 

• Click here to claim CPE Credit
• Click here to claim  CME Credit

Get a membership:

• Join for CPE Credit 
• Join for CME Credit 

References and resources: 

• Wood B, Huhn G. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?. Open Forum Infectious Diseases, Volume 8, Issue 12, December 2021. https://doi.org/10.1093/ofid/ofab542

Continuing Education Information:

Learning Objectives: 

1. Describe the proposed mechanism for weight gain due to integrase inhibitors
2. Identify co-morbid conditions with HIV that may influence medication selection

Dr. Wall is a member of the Janssen Speaker's Bureau. 
Dr. Hachey reports no actual or potential conflicts of interest associated with this episode.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-070-H01-P
Initial release date: 01/03/22
Expiration date: 01/03/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram